The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Non-cash lease expense | - | 0 |
| Net loss | -2,685,705 | -7,512,667 |
| Depreciation expense | 401 | 5,918 |
| Equity-based compensation | 473,384 | 1,141,409 |
| Interest receivable | -6,248 | -19,114 |
| Prepaid expenses | -242,342 | 316,100 |
| Deferred offering costs | 66,977 | 9,416 |
| Other assets | 0 | -1,624 |
| Accounts payable | -281,482 | -606,859 |
| Accrued liabilities | -45,361 | -397,580 |
| Net cash used in operating activities | -2,357,150 | -7,674,557 |
| Investment in property and equipment | 1,853 | 3,251 |
| Net cash used in investing activities | -1,853 | -3,251 |
| Proceeds from sale of common stock | 667,980 | 3,347,618 |
| Proceeds from exercise of warrants | - | 0 |
| Issuance costs from sale of common stock | 35,628 | 149,019 |
| Proceeds from exercise of stock options | 16,003 | 31,997 |
| Net cash provided by financing activities | 648,355 | 3,230,596 |
| Net change in cash and cash equivalents | -1,710,648 | -4,447,212 |
| Cash and cash equivalents at beginning of period | 10,017,942 | - |
| Cash and cash equivalents at end of period | 3,860,082 | - |
Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc. (CVKD)